Mohammad M. Mahmoud, MD, MS, reflects on AUA 2024, noting the importance of genetic testing for patients with advanced prostate cancer, particularly those with de novo metastases, and highlights the TARGET trial, which revealed that utilizing online tools for genetic testing resulted in a significant diagnosis rate of potentially actionable germline mutations.
Dr Mahmoud also discusses the therapeutic implications of studies like PSMAfore, which introduced lutetium-PSMA therapy for chemotherapy-naive patients, and expresses anticipation for emerging treatments like actinium-PSMA, offering promising options for patients who do not respond to conventional therapies.
Medscape © 2024 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: AUA 2024: Emerging Treatments and Testing for Advanced Prostate Cancer - Medscape - May 23, 2024.
Comments